

This activity, certified for CME/CE/CPE credit, is jointly provided by



Advances in HER2-Positive Breast Cancer: Novel Therapies and Adverse Event Management

A continuing education activity for nurse practitioners, PAs, clinical nurse specialists, advanced degree nurses, oncology and hematology nurses, pharmacists, and physicians.

Harborside Medical Education

Harborside Medical Education (HSME), a division of Harborside, is committed to advancing care for people with cancer and improving patient outcomes through professional continuing education (CE) activities in oncology that address practice gaps and promote change in learners' knowledge, competence and performance in both community and academic practice settings.

Release date: March 21, 2019

Estimated time to complete activity: 0.5 hour

Expiration date: March 21, 2020

Certified for CE by:

Annenberg Center for Health Sciences at Eisenhower

39000 Bob Hope Drive, Dinah Shore Bldg.
Rancho Mirage, CA 92270
Voice: 760-773-4500
Fax: 760-773-4513
E-mail: contactce@annenberg.net
© 2019, Annenberg Center for Health Sciences
at Eisenhower. All rights reserved.

Journal of the Advanced Practitioner in Oncology

94 North Woodhull Road
Huntington, NY 11743
Voice: 631-692-0800
Fax: 631-692-0805
E-mail: editor@advancedpractitioner.com

This certified activity is supported by an educational grant from Puma Biotechnology, Inc.

Faculty

Reshma Mahtani, DO, Sylvester Comprehensive Cancer Center, Miami, Florida

Lisa Hineman, MS, AOCN®, PHN, ANP-C, Los Angeles Cancer Network, Los Angeles, California

Intended Audience

The activity's target audience will consist of nurse practitioners, physician assistants, clinical nurse specialists, advanced degree nurses, oncology and hematology nurses, pharmacists, and physicians.

Learning Objectives

After completing this educational activity, participants should be able to:

1. Discuss the clinical significance of existing and emerging data in HER2+ breast cancer
2. Develop a strategy to effectively manage diarrhea and other adverse events associated with treatments for HER2+ breast cancer
3. Implement best practices for the management of HER2+ breast cancer brain metastases

Continuing Education

Statement of Credit—Participants who successfully complete this activity (including the submission of the post-test and evaluation form) will receive a statement of credit.



Physicians. This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education through the joint providership of the Annenberg Center for Health Sciences at Eisenhower and the *Journal of the Advanced Practitioner in Oncology*. The Annenberg Center is accredited by the ACCME to provide continuing medical education for physicians.

The Annenberg Center for Health Sciences at Eisenhower designates this enduring activity for a maximum of 0.5 *AMA PRA Category 1 Credits*[™]. Physicians should claim only the credit commensurate with the extent of their participation in the activity.



Nurses. The Annenberg Center for Health Sciences at Eisenhower is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.

A maximum of 0.5 contact hours may be earned for successful completion of this activity.

Provider approved by the California Board of Registered Nursing, Provider No. 13664, for 0.5 contact hours.



Pharmacists. The Annenberg Center for Health Sciences at Eisenhower is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This program has been assigned ACPE Universal Program #0797-9999-19-041-H01-P. This program is designated for up to 0.5 contact hours (0.05 CEUs) of continuing pharmacy education credit.

Financial Disclosures

All individuals in positions to control the content of this program (e.g., planners, faculty, content reviewers) are expected to disclose all financial relationships with commercial interests that may have a direct bearing on the subject matter of this continuing education activity. Annenberg Center for Health Sciences at Eisenhower has identified and resolved all conflicts of interest in accordance with the ACHS policies and procedures. Participants have the responsibility to assess the impact (if any) of the disclosed information on the educational value of the activity.

Disclosures

FACULTY

Dr. Mahtani has consulted for Amgen, Genentech, Lilly, Novartis, Pfizer, and Puma, and has received research support from Genentech.

Ms. Hineman has nothing to disclose.

ANNENBERG CENTER FOR HEALTH SCIENCES AT EISENHOWER

Staff at the Annenberg Center for Health Sciences at Eisenhower have no relevant commercial relationships to disclose.

LEAD NURSE PLANNER

Dorothy Caputo, MA, BSN, RN, EduPro Resources, LLC, has nothing to disclose.

PLANNERS

Harborside and Harborside Medical Education staff have no potential conflicts of interest to disclose.

CONTENT REVIEWERS

Monique Johnson, MD, CHCP, has nothing to disclose.

Kelley Mayden, MSN, FNP, AOCNP®, has served on speakers bureaus for Pfizer and Puma.

Wendy Vogel, MSN, FNP, AOCNP®, has served on speakers bureaus for AMAG, Celgene, Genentech, Ipsen, Lilly, and Novartis.

ARTICLE COPYWRITER

Barry A. Fiedel, PhD, OnPoint Medical Communications LLC, has nothing to disclose.

Disclaimer

This activity has been designed to provide continuing education that is focused on specific objectives. In selecting educational activities, clinicians should pay special attention to the relevance of those objectives and the application to their particular needs. The intent of all Annenberg Center for Health Sciences at Eisenhower educational opportunities is to provide learning that will improve patient care. Clinicians are encouraged to reflect on this activity and its applicability to their own patient population.

The opinions expressed in this activity are those of the faculty and reviewers and do not represent an endorsement by Annenberg Center for Health Sciences at Eisenhower of any specific therapeutics or approaches to diagnosis or patient management.

Product Disclosure

This educational activity may contain discussion of published as well as investigational uses of agents that are not approved by the US Food and Drug Administration. For additional information about approved uses, including approved indications, contraindications, and warnings, please refer to the prescribing information for each product.

How to Earn Credit

To access the learning assessment and evaluation form online, visit <https://education.annenberg.net/jadpro-her2article>

Statement of Credit: Participants who successfully complete this activity (including scoring of a minimum of 70% on the learning assessment) and complete and submit the evaluation form will be able to download a statement of credit.